Database Query Results : Ashwagandha, ,

Ash, Ashwagandha: Click to Expand ⟱
Features:
Withaferin A is a steroidal lactone derived from the medicinal plant Withania somnifera (commonly known as Ashwagandha).
The main active constituents of Ashwagandha leaves are alkaloids and steroidal lactones (commonly known as Withanolides).
-The main constituents of ashwagandha are withanolides such as withaferin A, alkaloids, steroidal lactones, tropine, and cuscohygrine.
Ashwagandha is an herb that may reduce stress, anxiety, and insomnia.
*-Ashwagandha is often characterized as an antioxidant.
-Some studies suggest that while ashwagandha may protect normal cells from oxidative damage, it can simultaneously stress cancer cells by tipping their redox balance toward cytotoxicity.
Pathways:
-Induction of Apoptosis and ROS Generation
-Hsp90 Inhibition and Proteasomal Degradation

Cell culture studies vary widely, typically ranging from low micromolar (e.g., 1–10 µM).
In animal models (commonly mice), Withaferin A has been administered in doses ranging from approximately 2 to 10 mg/kg body weight.
- General wellness, Ashwagandha supplements are sometimes taken in doses ranging from 300 mg to 600 mg of an extract (often standardized to contain a certain percentage of withanolides) once or twice daily.
- 400mg of WS extract was given 3X/day to schizophrenia patients. report#2001.
- Ashwagandha Pure 400mg/capsule is available from mcsformulas.com.

-Note half-life 4-6 hrs?.
BioAv
Pathways:
- well-recognized for promoting ROS in cancer cells, while no effect(or reduction) on normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Confusing results about Lowering AntiOxidant defense in Cancer Cells: NRF2↓, TrxR↓**, SOD↓, GSH↓ Catalase↓ HO1↓ GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, TIMP2, uPA↓, VEGF↓, ROCK1↓, NF-κB↓, CXCR4↓, SDF1↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓(combined with sulfor), DNMT1↓, DNMT3A↓, P53↑, HSP↓, Sp proteins↓, TET↑
- cause Cell cycle arrest : TumCCA↑, cyclin E↓, CDK2↓, CDK4↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, ERK↓, EMT↓, TOP1↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, OXPHOS↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, β-catenin↓, sox2↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, α↓, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells


Scientific Papers found: Click to Expand⟱
3166- Ash,    Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
- Review, Var, NA
"highlight2" >*p‑PPARγ↓, "highlight2" >*cardioP↑, "highlight2" >*AMPK↑, "highlight2" >*BioAv↝, "highlight2" >*Half-Life↝, "highlight2" >*Half-Life↝, "highlight2" >*Dose↑, "highlight2" >*chemoP↑, "highlight2" >IL6↓, "highlight2" >STAT3↓, "highlight2" >ROS↓, "highlight2" >OXPHOS↓, "highlight2" >PCNA↓, "highlight2" >LDH↓, "highlight2" >AMPK↑, "highlight2" >TumCCA↑, "highlight2" >NOTCH3↓, "highlight2" >Akt↓, "highlight2" >Bcl-2↓, "highlight2" >Casp3↑, "highlight2" >Apoptosis↑, "highlight2" >eff↑, "highlight2" >NF-kB↓, "highlight2" >CSCs↓, "highlight2" >HSP90↓, "highlight2" >PI3K↓, "highlight2" >FOXO3↑, "highlight2" >β-catenin/ZEB1↓, "highlight2" >N-cadherin↓, "highlight2" >EMT↓, "highlight2" >FASN↓, "highlight2" >ACLY↓, "highlight2" >ROS↑, "highlight2" >NRF2↑, "highlight2" >HO-1↑, "highlight2" >NQO1↑, "highlight2" >JNK↑, "highlight2" >mTOR↓, "highlight2" >neuroP↑, "highlight2" >*TNF-α↓, "highlight2" >*IL1β↓, "highlight2" >*IL6↓, "highlight2" >*IL8↓, "highlight2" >*IL18↓, "highlight2" >RadioS↑, "highlight2" >eff↑,
3175- Ash,  SFN,    Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
"highlight2" >DNMTs↓, "highlight2" >HDAC↓, "highlight2" >eff↑,
3174- Ash,    Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
"highlight2" >NF-kB↓, "highlight2" >angioG↓, "highlight2" >Inflam↓, "highlight2" >TumCP↓, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >Sp1/3/4↓, "highlight2" >VEGF↓, "highlight2" >angioG↓, "highlight2" >uPA↓, "highlight2" >PDGF↓, "highlight2" >MCP1↓, "highlight2" >ICAM-1↓, "highlight2" >*NRF2↑, "highlight2" >*hepatoP↑,
3173- Ash,    Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma
- in-vitro, neuroblastoma, NA
"highlight2" >GPx4↓, "highlight2" >HO-1↑, "highlight2" >lipid-P↑, "highlight2" >Keap1↓, "highlight2" >NRF2↑, "highlight2" >Ferroptosis↑,
3172- Ash,    Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis
- in-vitro, HCC, HepG2 - in-vitro, Nor, HL7702
"highlight2" >Keap1↑, "highlight2" >NRF2↓, "highlight2" >EMT↓, "highlight2" >TumCP↓, "highlight2" >TumCI↓, "highlight2" >selectivity↑, "highlight2" >*toxicity↓, "highlight2" >ROS↑, "highlight2" >MDA↑, "highlight2" >GSH↓, "highlight2" >Ferroptosis↑,
3171- Ash,    Unlocking the epigenetic code: new insights into triple-negative breast cancer
- Review, BC, NA
"highlight2" >DNMTs↓,
3170- Ash,    Withaferin A protects against hyperuricemia induced kidney injury and its possible mechanisms
- in-vitro, Nor, NRK52E - in-vivo, NA, NA
"highlight2" >*RenoP↑, "highlight2" >*hepatoP↑, "highlight2" >*creat↓, "highlight2" >*BUN↓, "highlight2" >*uricA↓, "highlight2" >*Apoptosis↓, "highlight2" >*α-SMA↓,
3169- Ash,    Withaferin A blocks formation of IFN-γ-induced metastatic cancer stem cells through inhibition of the CXCR4/CXCL12 pathway in the UP-LN1 carcinoma cell model
- in-vitro, GC, NA
"highlight2" >CXCR4↓, "highlight2" >CXCL12↓,
3168- Ash,    Withaferin A targeting both cancer stem cells and metastatic cancer stem cells in the UP-LN1 carcinoma cell model
- in-vitro, Var, NA
"highlight2" >CXCR4↓, "highlight2" >STAT3↓, "highlight2" >CSCs↓,
3167- Ash,    Withaferin A Inhibits the Proteasome Activity in Mesothelioma In Vitro and In Vivo
- in-vitro, MM, H226
"highlight2" >TumCP↓, "highlight2" >cMyc↓, "highlight2" >cFos↓, "highlight2" >cJun↓, "highlight2" >TIMP2↑, "highlight2" >Vim↓, "highlight2" >ROS↑, "highlight2" >BAX↑, "highlight2" >IKKα↑, "highlight2" >Casp3↑, "highlight2" >cl‑PARP↑,
3176- Ash,    Apoptosis is induced in leishmanial cells by a novel protein kinase inhibitor withaferin A and is facilitated by apoptotic topoisomerase I-DNA complex
- in-vitro, NA, NA
"highlight2" >PKCδ↓, "highlight2" >TOP1∅, "highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >DNAdam↑, "highlight2" >MMP↓, "highlight2" >Cyt‑c↑,
3165- Ash,    Inhibitory effect of withaferin A on Helicobacter pylori‑induced IL‑8 production and NF‑κB activation in gastric epithelial cells
- in-vitro, Nor, NA
"highlight2" >*IL8↓, "highlight2" >*Inflam↓,
3164- Ash,    Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3
"highlight2" >*hepatoP↑, "highlight2" >*IKKα↓, "highlight2" >*NLRP3↓, "highlight2" >*NRF2↑, "highlight2" >*AMPK↑, "highlight2" >*Inflam↓, "highlight2" >*Apoptosis↓, "highlight2" >*cl‑Casp3↓, "highlight2" >*cl‑PARP1↓, "highlight2" >*NLRP3↓, "highlight2" >*ROS↓, "highlight2" >*ALAT↓, "highlight2" >*AST↓, "highlight2" >*GSH↑,
3163- Ash,  Rad,    Withaferin A, a steroidal lactone, selectively protects normal lymphocytes against ionizing radiation induced apoptosis and genotoxicity via activation of ERK/Nrf-2/HO-1 axis
"highlight2" >*radioP↑, "highlight2" >selectivity↑, "highlight2" >*Casp3↓, "highlight2" >*DNAdam↓, "highlight2" >*ROS↓, "highlight2" >*GSH↓, "highlight2" >*NRF2↑, "highlight2" >*HO-1↑, "highlight2" >*Catalase↑, "highlight2" >*SOD↑, "highlight2" >*Prx↑, "highlight2" >*ERK↑,
3162- Ash,    Molecular insights into cancer therapeutic effects of the dietary medicinal phytochemical withaferin A
- Review, Var, NA
"highlight2" >lipid-P↓, "highlight2" >SOD↑, "highlight2" >GPx↑, "highlight2" >P53↑, "highlight2" >Bcl-2↑, "highlight2" >E6↓, "highlight2" >E7↓, "highlight2" >pRB↑, "highlight2" >CycB↑, "highlight2" >CDC2↑, "highlight2" >P21↑, "highlight2" >PCNA↓, "highlight2" >ALDH1A1↓, "highlight2" >Vim↓, "highlight2" >Glycolysis↓, "highlight2" >cMyc↓, "highlight2" >BAX↑, "highlight2" >NF-kB↓, "highlight2" >Casp3↑, "highlight2" >CHOP↑, "highlight2" >DR5↑, "highlight2" >ERK↓, "highlight2" >Wnt↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >Akt↓, "highlight2" >HSP90↓,
3161- Ash,    Withaferin A inhibits ferroptosis and protects against intracerebral hemorrhage
- in-vivo, Stroke, NA
"highlight2" >*neuroP↑, "highlight2" >*MDA↓, "highlight2" >*ROS↓, "highlight2" >*SOD↑, "highlight2" >*GPx↑, "highlight2" >*NRF2↑, "highlight2" >*HO-1↑,
3160- Ash,    Withaferin A: A Pleiotropic Anticancer Agent from the Indian Medicinal Plant Withania somnifera (L.) Dunal
- Review, Var, NA
"highlight2" >TumCCA↑, "highlight2" >H3↑, "highlight2" >P21↑, "highlight2" >cycA1↓, "highlight2" >CycB↓, "highlight2" >cycE↓, "highlight2" >CDC2↓, "highlight2" >CHK1↓, "highlight2" >Chk2↓, "highlight2" >p38↑, "highlight2" >MAPK↑, "highlight2" >E6↓, "highlight2" >E7↓, "highlight2" >P53↑, "highlight2" >Akt↓, "highlight2" >FOXO3↑, "highlight2" >ROS↑, "highlight2" >γH2AX↑, "highlight2" >MMP↓, "highlight2" >mitResp↓, "highlight2" >eff↑, "highlight2" >TumCD↑, "highlight2" >Mcl-1↓, "highlight2" >ER Stress↑, "highlight2" >ATF4↑, "highlight2" >ATF3↑, "highlight2" >CHOP↑, "highlight2" >NOTCH↓, "highlight2" >NF-kB↓, "highlight2" >Bcl-2↓, "highlight2" >STAT3↓, "highlight2" >CDK1↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >N-cadherin↓, "highlight2" >EMT↓, "highlight2" >Cyt‑c↑, "highlight2" >eff↑, "highlight2" >CDK4↓, "highlight2" >p‑RB1↓, "highlight2" >PARP↑, "highlight2" >cl‑Casp3↑, "highlight2" >cl‑Casp9↑, "highlight2" >NRF2↑, "highlight2" >ER-α36↓, "highlight2" >LDHA↓, "highlight2" >lipid-P↑, "highlight2" >AP-1↓, "highlight2" >COX2↓, "highlight2" >RenoP↑, "highlight2" >PDGFR-BB↓, "highlight2" >SIRT3↑, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >NADPH↑, "highlight2" >NQO1↑, "highlight2" >GSR↑, "highlight2" >HO-1↑, "highlight2" >*SOD2↑, "highlight2" >*Prx↑, "highlight2" >*Casp3?, "highlight2" >eff↑, "highlight2" >Snail↓, "highlight2" >Slug↓, "highlight2" >Vim↓, "highlight2" >CSCs↓, "highlight2" >HEY1↓, "highlight2" >MMPs↓, "highlight2" >VEGF↓, "highlight2" >uPA↓, "highlight2" >*toxicity↓, "highlight2" >CDK2↓, "highlight2" >CDK4↓, "highlight2" >HSP90↓,
3159- Ash,    Neuroprotective effects of Withania somnifera in the SH-SY5Y Parkinson cell model
- in-vitro, Park, SH-SY5Y
"highlight2" >*neuroP↑, "highlight2" >*Inflam↓, "highlight2" >*ROS↓, "highlight2" >*cognitive↑, "highlight2" >*memory↑, "highlight2" >*GPx↑, "highlight2" >*Prx↓, "highlight2" >*ATP↑, "highlight2" >*Vim↓, "highlight2" >*mtDam↓,
3158- Ash,    Natural products triptolide, celastrol, and withaferin A inhibit the chaperone activity of peroxiredoxin I
- Study, NA, NA
"highlight2" >Prx↓,
3673- Ash,    An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda
- Review, NA, NA
"highlight2" >*cognitive↑, "highlight2" >*Inflam↓, "highlight2" >*Strength↑, "highlight2" >*VitC↑, "highlight2" >*memory↑,
4303- Ash,    Ashwagandha (Withania somnifera)—Current Research on the Health-Promoting Activities: A Narrative Review
- Review, AD, NA
"highlight2" >*neuroP↑, "highlight2" >*Sleep↑, "highlight2" >*Inflam↓, "highlight2" >*cardioP↑, "highlight2" >*cognitive↑, "highlight2" >*Aβ↓, "highlight2" >*TNF-α↓, "highlight2" >*IL1β↓, "highlight2" >*IL6↓, "highlight2" >*MCP1↓, "highlight2" >*lipid-P↓, "highlight2" >*tau↓, "highlight2" >*ROS↓, "highlight2" >*BBB↑, "highlight2" >*AChE↓, "highlight2" >*GSH↑, "highlight2" >*GSTs↑, "highlight2" >*GSR↑, "highlight2" >*GPx↑, "highlight2" >*SOD↑, "highlight2" >*Catalase↑, "highlight2" >ChemoSen↑, "highlight2" >*Strength↑,
3689- Ash,    Ashwagandha attenuates TNF-α- and LPS-induced NF-κB activation and CCL2 and CCL5 gene expression in NRK-52E cells
- in-vitro, NA, NRK52E
"highlight2" >*RenoP↑, "highlight2" >*NF-kB↓, "highlight2" >*MCP1↓, "highlight2" >*RANTES↓,
3688- Ash,    Withaferin A Suppresses Beta Amyloid in APP Expressing Cells: Studies for Tat and Cocaine Associated Neurological Dysfunctions
- NA, AD, SH-SY5Y
"highlight2" >*Aβ↓, "highlight2" >*neuroP↑,
3687- Ash,    Role of Withaferin A and Its Derivatives in the Management of Alzheimer’s Disease: Recent Trends and Future Perspectives
- Review, AD, NA
"highlight2" >*Aβ↓, "highlight2" >*tau↓, "highlight2" >*HSPs↝, "highlight2" >*antiOx↑, "highlight2" >*ROS↓, "highlight2" >*Inflam↓, "highlight2" >*neuroP↑, "highlight2" >*cognitive↑, "highlight2" >*NF-kB↓, "highlight2" >*HO-1↑, "highlight2" >*memory↑, "highlight2" >*AChE↓, "highlight2" >*BChE↓, "highlight2" >*ChAT↑, "highlight2" >*Ach↑,
3686- Ash,    Adaptogenic and Anxiolytic Effects of Ashwagandha Root Extract in Healthy Adults: A Double-blind, Randomized, Placebo-controlled Clinical Study
- Study, NA, NA
"highlight2" >*Sleep↑,
3685- Ash,    Withania somnifera as a Potential Anxiolytic and Anti-inflammatory Candidate Against Systemic Lipopolysaccharide-Induced Neuroinflammation
- in-vivo, NA, NA
"highlight2" >*TNF-α↓, "highlight2" >*IL1β↓, "highlight2" >*IL6↓, "highlight2" >*iNOS↓, "highlight2" >*COX2↓, "highlight2" >*NOX↓, "highlight2" >*cognitive↑, "highlight2" >*Inflam↓, "highlight2" >*NF-kB↓,
3676- Ash,    Effect of Withania somnifera (Ashwagandha) root extract on amelioration of oxidative stress and autoantibodies production in collagen-induced arthritic rats
- in-vivo, Arthritis, NA
"highlight2" >*CRP↓, "highlight2" >*ROS↓, "highlight2" >*lipid-P↓, "highlight2" >*GSTs↓, "highlight2" >*GSH↑, "highlight2" >*antiOx↑, "highlight2" >*Inflam↓,
3675- Ash,    Ashwagandha (Withania somnifera) Reverses β-Amyloid1-42 Induced Toxicity in Human Neuronal Cells: Implications in HIV-Associated Neurocognitive Disorders (HAND)
"highlight2" >*memory↑, "highlight2" >*neuroP↑, "highlight2" >*Aβ↓, "highlight2" >*LDH↓, "highlight2" >*PPARγ↑, "highlight2" >*cognitive↑,
3674- Ash,    Ashwagandha in brain disorders: A review of recent developments
- Review, NA, NA
"highlight2" >*neuroP↑,
3157- Ash,    Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass
- in-vivo, Ovarian, A2780S
"highlight2" >*cachexia↑, "highlight2" >*UPR↑, "highlight2" >Strength↑,
3672- Ash,    Critical review of the Withania somnifera (L.) Dunal: ethnobotany, pharmacological efficacy, and commercialization significance in Africa
- Review, NA, NA
"highlight2" >*cardioP↑, "highlight2" >*antiOx↑, "highlight2" >*ROS↓, "highlight2" >*neuroP↑, "highlight2" >*Inflam↓, "highlight2" >*Apoptosis↓,
3671- Ash,    Withania somnifera showed neuroprotective effect and increase longevity in Drosophila Alzheimer’s disease model
- in-vivo, AD, NA
"highlight2" >*OS↑, "highlight2" >*BACE↓,
3670- Ash,    Neurodegenerative diseases and Withania somnifera (L.): An update
- Review, AD, NA - Review, Park, NA
"highlight2" >*Apoptosis↓, "highlight2" >*Inflam↓, "highlight2" >*ROS↓, "highlight2" >*neuroP↑,
3669- Ash,    Withanamides in Withania somnifera fruit protect PC-12 cells from beta-amyloid responsible for Alzheimer's diseas
- in-vitro, AD, PC12
"highlight2" >*lipid-P↓, "highlight2" >*antiOx↑,
3668- Ash,    Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver
- NA, AD, NA
"highlight2" >*Aβ↓, "highlight2" >*cognitive↑,
3179- Ash,    Withaferin A inhibits JAK/STAT3 signaling and induces apoptosis of human renal carcinoma Caki cells
- in-vitro, RCC, Caki-1
"highlight2" >JAK↓, "highlight2" >STAT3↓, "highlight2" >Apoptosis↑,
3178- Ash,    Withaferin A Inhibits Neutrophil Adhesion, Migration, and Respiratory Burst and Promotes Timely Neutrophil Apoptosis
- Review, Nor, NA
"highlight2" >ITGB1↓,
3177- Ash,    Emerging Role of Hypoxia-Inducible Factors (HIFs) in Modulating Autophagy: Perspectives on Cancer Therapy
- Review, Var, NA
"highlight2" >Hif1a↓, "highlight2" >ROS↑, "highlight2" >ER Stress↑,
1181- Ash,    Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
"highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >EMT↓, "highlight2" >p‑SMAD2↓, "highlight2" >p‑SMAD3↓, "highlight2" >p‑NF-kB↓,
1363- Ash,  doxoR,    Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, CaOV3 - in-vivo, NA, NA
"highlight2" >ChemoSen↑, "highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >TumCCA↑, "highlight2" >LC3B↑, "highlight2" >TumCG↓, "highlight2" >cl‑Casp3↑,
1362- Ash,  GEM,    Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A
- in-vitro, PC, PANC1 - in-vitro, PC, Hs766t
"highlight2" >ChemoSen↑, "highlight2" >ROS↑, "highlight2" >Apoptosis↑, "highlight2" >TumCMig↓, "highlight2" >F-actin↓, "highlight2" >YMcells↓, "highlight2" >NF-kB↓,
1361- Ash,  SRF,    Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells
- in-vitro, Liver, HUH7 - in-vivo, Liver, HUH7
"highlight2" >TrxR↓, "highlight2" >ROS↑, "highlight2" >DNA-PK↑, "highlight2" >ER Stress↑, "highlight2" >Apoptosis↑, "highlight2" >eff↓,
1360- Ash,  immuno,    Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
- in-vitro, Lung, H1650 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
"highlight2" >PD-L1↑, "highlight2" >eff↓, "highlight2" >ROS↑, "highlight2" >ER Stress↑, "highlight2" >Apoptosis↑, "highlight2" >BAX↑, "highlight2" >Bak↑, "highlight2" >BAD↑, "highlight2" >Bcl-2↓, "highlight2" >XIAP↓, "highlight2" >survivin↓, "highlight2" >cl‑PARP↑, "highlight2" >CHOP↑, "highlight2" >p‑eIF2α↑, "highlight2" >ICD↑, "highlight2" >eff↑,
1359- Ash,    Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
"highlight2" >MMP↓, "highlight2" >Alix/AIP‑1↓, "highlight2" >ROS↑, "highlight2" >Paraptosis↑, "highlight2" >ER Stress↝,
1358- Ash,    Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms
- Review, Var, NA
"highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >TumAuto↑, "highlight2" >Ferroptosis↑, "highlight2" >TumCP↓, "highlight2" >CSCs↓, "highlight2" >TumMeta↓, "highlight2" >EMT↓, "highlight2" >angioG↓, "highlight2" >Vim↓, "highlight2" >HSP90↓, "highlight2" >annexin II↓, "highlight2" >m-FAM72A↓, "highlight2" >BCR-ABL↓, "highlight2" >Mortalin↓, "highlight2" >NRF2↓, "highlight2" >cMYB↓, "highlight2" >ROS↑, "highlight2" >ChemoSen↑, "highlight2" >eff↑, "highlight2" >ChemoSen↑, "highlight2" >ChemoSen↑, "highlight2" >eff↑, "highlight2" >*BioAv↓, "highlight2" >ROCK1↓, "highlight2" >TumCI↓, "highlight2" >Sp1/3/4↓, "highlight2" >VEGF↓, "highlight2" >Hif1a↓, "highlight2" >EGFR↓,
1357- Ash,    Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways
- in-vitro, GBM, U87MG - in-vitro, GBM, U251 - in-vitro, GBM, GL26
"highlight2" >TumCP↓, "highlight2" >TumCCA↑, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >p70S6↓, "highlight2" >p85S6K↓, "highlight2" >AMPKα↑, "highlight2" >TSC2↑, "highlight2" >HSP70/HSPA5↑, "highlight2" >HO-1↑, "highlight2" >HSF1↓, "highlight2" >Apoptosis↑, "highlight2" >ROS↑, "highlight2" >eff↓,
1356- Ash,    Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells
- in-vitro, CRC, HCT116
"highlight2" >ROS↑, "highlight2" >TumCCA↑, "highlight2" >MMP↓, "highlight2" >TumCG↓, "highlight2" >Apoptosis↑, "highlight2" >JNK↝,
1355- Ash,    Withaferin A-Induced Apoptosis in Human Breast Cancer Cells Is Mediated by Reactive Oxygen Species
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Nor, HMEC
"highlight2" >eff↑, "highlight2" >mt-ROS↑, "highlight2" >mitResp↓, "highlight2" >OXPHOS↓, "highlight2" >compIII↑, "highlight2" >BAX↑, "highlight2" >Bak↑, "highlight2" >other↓, "highlight2" >ATP∅, "highlight2" >*ROS∅,
1364- Ash,    Withaferin a Triggers Apoptosis and DNA Damage in Bladder Cancer J82 Cells through Oxidative Stress
- in-vitro, Bladder, J82
"highlight2" >cl‑Casp3↑, "highlight2" >cl‑Casp8↑, "highlight2" >cl‑Casp9↑, "highlight2" >cl‑PARP↑, "highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >DNAdam↑, "highlight2" >eff↓,
1180- Ash,    Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis
- in-vitro, Liver, HepG2
"highlight2" >IDH1↑, "highlight2" >Glycolysis↓, "highlight2" >P53↑, "highlight2" >Hif1a↓,
1179- Ash,    Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
"highlight2" >TumCP↓, "highlight2" >TumCMig↓, "highlight2" >STAT3↓, "highlight2" >TumVol↓, "highlight2" >TumW↓,
1178- Ash,    Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor
- in-vitro, Nor, HUVECs - in-vivo, NA, NA
"highlight2" >*VEGF↓, "highlight2" >*angioG↓, "highlight2" >*ascitic↓, "highlight2" >*Sp1/3/4↓,
1177- Ash,    Withaferin A downregulates COX-2/NF-κB signaling and modulates MMP-2/9 in experimental endometriosis
- in-vivo, EC, NA
"highlight2" >TumVol↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >NF-kB↓, "highlight2" >COX2↓, "highlight2" >NO↓, "highlight2" >IL1β↓, "highlight2" >IL6↓,
1176- Ash,    Metabolic Alterations in Mammary Cancer Prevention by Withaferin A in a Clinically Relevant Mouse Model
- in-vivo, NA, NA
"highlight2" >TumVol↓, "highlight2" >Apoptosis↑, "highlight2" >Glycolysis↓, "highlight2" >PKM2↓, "highlight2" >PGK1↓, "highlight2" >ALDOAiso2↓,
1174- Ash,    Withaferin A Suppresses Estrogen Receptor-α Expression in Human Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vivo, BC, MDA-MB-231 - in-vitro, BC, T47D
"highlight2" >p‑P53↑, "highlight2" >Apoptosis↑, "highlight2" >ERα↓,
1173- Ash,    Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling
- in-vitro, EC, K1 - in-vitro, Nor, THESCs
"highlight2" >TumCP↓, "highlight2" >*toxicity↓, "highlight2" >Apoptosis↑, "highlight2" >TumCCA↑, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >p‑SMAD2↓, "highlight2" >TGF-β↓, "highlight2" >*toxicity↓,
1172- Ash,    Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
"highlight2" >FASN↓, "highlight2" >ACLY↓, "highlight2" >ACC1↓, "highlight2" >CPT1A↓, "highlight2" >SREBP1↓,
1373- Ash,    Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells
- in-vitro, Kidney, Caki-1
"highlight2" >ER Stress↑, "highlight2" >p‑eIF2α↑, "highlight2" >XBP-1↑, "highlight2" >GRP78/BiP↑, "highlight2" >CHOP↑, "highlight2" >eff↓,
3156- Ash,    Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug
- Review, Var, NA
"highlight2" >MAPK↑, "highlight2" >p38↑, "highlight2" >BAX↑, "highlight2" >BIM↑, "highlight2" >CHOP↑, "highlight2" >ROS↑, "highlight2" >DR5↑, "highlight2" >Apoptosis↑, "highlight2" >Ferroptosis↑, "highlight2" >GPx4↓, "highlight2" >BioAv↝, "highlight2" >HSP90↓, "highlight2" >RET↓, "highlight2" >E6↓, "highlight2" >E7↓, "highlight2" >Akt↓, "highlight2" >cMET↓, "highlight2" >Glycolysis↓, "highlight2" >TCA↓, "highlight2" >NOTCH1↓, "highlight2" >STAT3↓, "highlight2" >AP-1↓, "highlight2" >PI3K↓, "highlight2" >eIF2α↓, "highlight2" >HO-1↑, "highlight2" >TumCCA↑, "highlight2" >CDK1↓, "highlight2" >*hepatoP↑, "highlight2" >*GSH↑, "highlight2" >*NRF2↑, "highlight2" >Wnt↓, "highlight2" >EMT↓, "highlight2" >uPA↓, "highlight2" >CSCs↓, "highlight2" >Nanog↓, "highlight2" >SOX2↓, "highlight2" >CD44↓, "highlight2" >lactateProd↓, "highlight2" >Iron↑, "highlight2" >NF-kB↓,
3155- Ash,    Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera
- Review, Var, NA
"highlight2" >Half-Life↝, "highlight2" >Inflam↓, "highlight2" >antiOx↓, "highlight2" >angioG↓, "highlight2" >ROS↑, "highlight2" >BAX↑, "highlight2" >Bak↑, "highlight2" >E6↓, "highlight2" >E7↓, "highlight2" >P53↑, "highlight2" >Casp3↑, "highlight2" >cl‑PARP↑, "highlight2" >STAT3↓, "highlight2" >eff↑, "highlight2" >HSP90↓, "highlight2" >TGF-β↓, "highlight2" >TNF-α↓, "highlight2" >EMT↑, "highlight2" >mTOR↓, "highlight2" >NOTCH1↓, "highlight2" >p‑Akt↓, "highlight2" >NF-kB↓, "highlight2" >Dose↝,
3154- Ash,    Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts – A double blind, crossover study in healthy adults
"highlight2" >BioAv↑, "highlight2" >BioAv↓,
2388- Ash,    Withaferin A decreases glycolytic reprogramming in breast cancer
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468 - in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-453
"highlight2" >GlucoseCon↓, "highlight2" >lactateProd↓, "highlight2" >ATP↓, "highlight2" >Glycolysis↓, "highlight2" >GLUT1↓, "highlight2" >HK2↓, "highlight2" >PKM2↓, "highlight2" >cMyc↓, "highlight2" >Warburg↓, "highlight2" >cMyc↓,
2003- Ash,    Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Nor, TIG-1 - in-vitro, PC, LNCaP
"highlight2" >TumCD↑, "highlight2" >selectivity↑, "highlight2" >cFos↑, "highlight2" >ROS↑, "highlight2" >*ROS∅, "highlight2" >HSP70/HSPA5↑, "highlight2" >Apoptosis↑, "highlight2" >ER Stress↑, "highlight2" >TumCCA↑,
2002- Ash,    Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology
- Review, Var, NA
"highlight2" >antiOx↑, "highlight2" >Inflam↓, "highlight2" >TumCP↓, "highlight2" >OS↑, "highlight2" >RadioS↑, "highlight2" >radioP↑, "highlight2" >chemoP↑,
2001- Ash,    Withania somnifera: from prevention to treatment of cancer
- Review, Var, NA
"highlight2" >toxicity↓, "highlight2" >TumW↓, "highlight2" >Dose?, "highlight2" >eff↝, "highlight2" >Ki-67↓, "highlight2" >survivin↓, "highlight2" >XIAP↓, "highlight2" >PERK↑, "highlight2" >p‑RSK↑, "highlight2" >CHOP↑, "highlight2" >DR5↑, "highlight2" >Dose↝, "highlight2" >BG↓, "highlight2" >DNMTs↓,
1433- Ash,  SFN,    A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231
"highlight2" >eff↑, "highlight2" >Bcl-2↓, "highlight2" >BAX↑, "highlight2" >tumCV↓, "highlight2" >DNMT1↓, "highlight2" >DNMT3A↓, "highlight2" >HDAC↓,
1142- Ash,    Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer
- Review, BC, MCF-7 - NA, BC, MDA-MB-231 - NA, Nor, HMEC
"highlight2" >Apoptosis↑, "highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >OXPHOS↓, "highlight2" >*ROS∅, "highlight2" >Bcl-2↓, "highlight2" >XIAP↓, "highlight2" >survivin↓, "highlight2" >DR5↑, "highlight2" >IKKα↓, "highlight2" >NF-kB↓, "highlight2" >selectivity↑, "highlight2" >*ROS∅, "highlight2" >eff↓, "highlight2" >Paraptosis↑,
1372- Ash,    Withaferin-A Induces Apoptosis in Osteosarcoma U2OS Cell Line via Generation of ROS and Disruption of Mitochondrial Membrane Potential
- in-vitro, OS, U2OS
"highlight2" >Apoptosis↑, "highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >Casp3↑,
1371- Ash,    Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic cell death of human myeloid leukemia HL-60 cells by a dietary compound withaferin A with concomitant protection by N-acetyl cysteine
- in-vitro, AML, HL-60
"highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >cl‑Casp3↑, "highlight2" >cl‑Casp9↑, "highlight2" >cl‑PARP↑, "highlight2" >eff↓,
1370- Ash,    Withaferin A induces mitochondrial-dependent apoptosis in non-small cell lung cancer cells via generation of reactive oxygen species
- in-vitro, Lung, A549
"highlight2" >ROS↑, "highlight2" >eff↓,
1369- Ash,    Withaferin A inhibits cell proliferation of U266B1 and IM-9 human myeloma cells by inducing intrinsic apoptosis
- in-vitro, Melanoma, U266
"highlight2" >tumCV↓, "highlight2" >Apoptosis↑, "highlight2" >BAX↑, "highlight2" >Cyt‑c↑, "highlight2" >Bcl-2↓, "highlight2" >cl‑PARP↑, "highlight2" >cl‑Casp3↑, "highlight2" >cl‑Casp9↑, "highlight2" >ROS↑, "highlight2" >eff↓,
1368- Ash,  Cisplatin,    Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’
- in-vitro, Colon, HT-29 - in-vitro, BC, MDA-MB-231
"highlight2" >tumCV↓, "highlight2" >*toxicity↓, "highlight2" >ROS↑, "highlight2" >mitResp↓, "highlight2" >ChemoSen↑,
1367- Ash,    An anti-cancerous protein fraction from Withania somnifera induces ROS-dependent mitochondria-mediated apoptosis in human MDA-MB-231 breast cancer cells
- in-vitro, BC, MDA-MB-231
"highlight2" >Apoptosis↑, "highlight2" >ROS↑, "highlight2" >Bax:Bcl2↑, "highlight2" >MMP↓, "highlight2" >Casp3↑, "highlight2" >TumCCA↑,
1366- Ash,    Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling
- in-vitro, BC, MCF-7
"highlight2" >ROS↑, "highlight2" >P53↑,
1365- Ash,    Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells
- in-vitro, Oral, Ca9-22 - in-vitro, Oral, CAL27
"highlight2" >ROS↑, "highlight2" >*toxicity↓, "highlight2" >Apoptosis↑, "highlight2" >TumCCA↑, "highlight2" >MMP↓, "highlight2" >p‑γH2AX↑, "highlight2" >DNAdam↑, "highlight2" >eff↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 75

Results for Effect on Cancer/Diseased Cells:
ACC1↓,1,   ACLY↓,2,   Akt↓,5,   p‑Akt↓,1,   ALDH1A1↓,1,   ALDOAiso2↓,1,   Alix/AIP‑1↓,1,   AMPK↑,1,   AMPKα↑,1,   angioG↓,4,   annexin II↓,1,   antiOx↓,1,   antiOx↑,1,   AP-1↓,2,   Apoptosis↑,18,   ATF3↑,1,   ATF4↑,1,   ATP↓,1,   ATP∅,1,   BAD↑,1,   Bak↑,3,   BAX↑,8,   Bax:Bcl2↑,1,   Bcl-2↓,6,   Bcl-2↑,1,   BCR-ABL↓,1,   BG↓,1,   BIM↑,1,   BioAv↓,1,   BioAv↑,1,   BioAv↝,1,   Casp3↑,6,   cl‑Casp3↑,5,   cl‑Casp8↑,1,   cl‑Casp9↑,4,   CD44↓,1,   CDC2↓,1,   CDC2↑,1,   CDK1↓,2,   CDK2↓,1,   CDK4↓,2,   cFos↓,1,   cFos↑,1,   chemoP↑,1,   ChemoSen↑,7,   CHK1↓,1,   Chk2↓,1,   CHOP↑,6,   cJun↓,1,   cMET↓,1,   cMYB↓,1,   cMyc↓,4,   compIII↑,1,   COX2↓,2,   CPT1A↓,1,   CSCs↓,5,   CXCL12↓,1,   CXCR4↓,2,   cycA1↓,1,   CycB↓,1,   CycB↑,1,   cycE↓,1,   Cyt‑c↑,3,   DNA-PK↑,1,   DNAdam↑,5,   DNMT1↓,1,   DNMT3A↓,1,   DNMTs↓,3,   Dose?,1,   Dose↝,2,   DR5↑,4,   E6↓,4,   E7↓,4,   eff↓,10,   eff↑,12,   eff↝,1,   EGFR↓,1,   eIF2α↓,1,   p‑eIF2α↑,2,   EMT↓,6,   EMT↑,1,   ER Stress↑,6,   ER Stress↝,1,   ER-α36↓,1,   ERK↓,1,   ERα↓,1,   F-actin↓,1,   m-FAM72A↓,1,   FASN↓,2,   Ferroptosis↑,4,   FOXO3↑,2,   GlucoseCon↓,1,   GLUT1↓,1,   Glycolysis↓,5,   GPx↑,1,   GPx4↓,2,   GRP78/BiP↑,1,   GSH↓,2,   GSR↑,1,   H3↑,1,   Half-Life↝,1,   HDAC↓,2,   HEY1↓,1,   Hif1a↓,3,   HK2↓,1,   HO-1↑,5,   HSF1↓,1,   HSP70/HSPA5↑,2,   HSP90↓,6,   ICAM-1↓,1,   ICD↑,1,   IDH1↑,1,   IKKα↓,1,   IKKα↑,1,   IL1β↓,1,   IL6↓,2,   Inflam↓,3,   Iron↑,1,   ITGB1↓,1,   JAK↓,1,   JNK↑,1,   JNK↝,1,   Keap1↓,1,   Keap1↑,1,   Ki-67↓,1,   lactateProd↓,2,   LC3B↑,1,   LDH↓,1,   LDHA↓,1,   lipid-P↓,1,   lipid-P↑,2,   MAPK↑,2,   Mcl-1↓,1,   MCP1↓,1,   MDA↑,1,   mitResp↓,3,   MMP↓,9,   MMP2↓,2,   MMP9↓,2,   MMPs↓,1,   Mortalin↓,1,   mTOR↓,3,   N-cadherin↓,2,   NADPH↑,1,   Nanog↓,1,   neuroP↑,1,   NF-kB↓,9,   p‑NF-kB↓,1,   NO↓,1,   NOTCH↓,1,   NOTCH1↓,2,   NOTCH3↓,1,   NQO1↑,2,   NRF2↓,2,   NRF2↑,3,   OS↑,1,   other↓,1,   OXPHOS↓,3,   P21↑,2,   p38↑,2,   P53↑,5,   p‑P53↑,1,   p70S6↓,1,   p85S6K↓,1,   Paraptosis↑,2,   PARP↑,1,   cl‑PARP↑,6,   PCNA↓,2,   PD-L1↑,1,   PDGF↓,1,   PDGFR-BB↓,1,   PERK↑,1,   PGK1↓,1,   PI3K↓,2,   PKCδ↓,1,   PKM2↓,2,   pRB↑,1,   Prx↓,1,   radioP↑,1,   RadioS↑,2,   p‑RB1↓,1,   RenoP↑,1,   RET↓,1,   ROCK1↓,1,   ROS↓,1,   ROS↑,27,   mt-ROS↑,1,   p‑RSK↑,1,   selectivity↑,4,   SIRT3↑,1,   Slug↓,1,   p‑SMAD2↓,2,   p‑SMAD3↓,1,   Snail↓,1,   SOD↑,1,   SOX2↓,1,   Sp1/3/4↓,2,   SREBP1↓,1,   STAT3↓,7,   Strength↑,1,   survivin↓,3,   TCA↓,1,   TGF-β↓,2,   TIMP2↑,1,   TNF-α↓,1,   TOP1∅,1,   toxicity↓,1,   TrxR↓,1,   TSC2↑,1,   TumAuto↑,1,   TumCCA↑,11,   TumCD↑,2,   TumCG↓,2,   TumCI↓,5,   TumCMig↓,5,   TumCP↓,8,   tumCV↓,3,   TumMeta↓,1,   TumVol↓,3,   TumW↓,2,   uPA↓,3,   VEGF↓,3,   Vim↓,4,   Warburg↓,1,   Wnt↓,2,   XBP-1↑,1,   XIAP↓,3,   YMcells↓,1,   β-catenin/ZEB1↓,3,   γH2AX↑,1,   p‑γH2AX↑,1,  
Total Targets: 231

Results for Effect on Normal Cells:
Ach↑,1,   AChE↓,2,   ALAT↓,1,   AMPK↑,2,   angioG↓,1,   antiOx↑,4,   Apoptosis↓,4,   ascitic↓,1,   AST↓,1,   ATP↑,1,   Aβ↓,5,   BACE↓,1,   BBB↑,1,   BChE↓,1,   BioAv↓,1,   BioAv↝,1,   BUN↓,1,   cachexia↑,1,   cardioP↑,3,   Casp3?,1,   Casp3↓,1,   cl‑Casp3↓,1,   Catalase↑,2,   ChAT↑,1,   chemoP↑,1,   cognitive↑,7,   COX2↓,1,   creat↓,1,   CRP↓,1,   DNAdam↓,1,   Dose↑,1,   ERK↑,1,   GPx↑,3,   GSH↓,1,   GSH↑,4,   GSR↑,1,   GSTs↓,1,   GSTs↑,1,   Half-Life↝,2,   hepatoP↑,4,   HO-1↑,3,   HSPs↝,1,   IKKα↓,1,   IL18↓,1,   IL1β↓,3,   IL6↓,3,   IL8↓,2,   Inflam↓,10,   iNOS↓,1,   LDH↓,1,   lipid-P↓,3,   MCP1↓,2,   MDA↓,1,   memory↑,4,   mtDam↓,1,   neuroP↑,9,   NF-kB↓,3,   NLRP3↓,2,   NOX↓,1,   NRF2↑,5,   OS↑,1,   cl‑PARP1↓,1,   PPARγ↑,1,   p‑PPARγ↓,1,   Prx↓,1,   Prx↑,2,   radioP↑,1,   RANTES↓,1,   RenoP↑,2,   ROS↓,9,   ROS∅,4,   Sleep↑,2,   SOD↑,3,   SOD2↑,1,   Sp1/3/4↓,1,   Strength↑,2,   tau↓,2,   TNF-α↓,3,   toxicity↓,6,   UPR↑,1,   uricA↓,1,   VEGF↓,1,   Vim↓,1,   VitC↑,1,   α-SMA↓,1,  
Total Targets: 85

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:36  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page